My Treatment Approach: Treatment Selection for Relapsed/Refractory Follicular Lymphoma - Episode 6
Practical Considerations for Tafasitamab-R2 and Epcoritamab-R2 in Community Practice
Building on the prior case, this segment explores the practical distinctions between tafasitamab-R2 and epcoritamab-R2 in routine practice. Dr. Mehta notes that tafasitamab-based therapy is generally easier to administer within community oncology settings because it does not require the step-up dosing protocols or intensive monitoring associated with bispecific antibodies. In contrast, epcoritamab-R2, although highly effective, introduces complexities such as CRS risk, ICANS monitoring, and potential need for rapid escalation to emergency or extended care services. NP Bailey addresses patient education and adherence, emphasizing that epcoritamab-containing regimens require robust teaching around symptom recognition, infection prevention, and timely reporting of adverse effects. She underscores the importance of ensuring patients understand the seriousness of potential bispecific-related toxicities, even if uncommon, and have clear instructions for seeking care. The segment also highlights the operational realities of community practice, where many clinicians still rely on academic centers to initiate bispecific therapy before transitioning patients back to local care. Dr. Mehta notes the value of extended care clinics that can manage lower-grade CRS on an outpatient basis, reducing hospital admissions and relieving pressure on inpatient services. This segment equips clinicians with a pragmatic understanding of how to safely and effectively integrate novel antibody-based regimens into diverse practice environments.
Building on the prior case, this segment explores the practical distinctions between tafasitamab-R2 and epcoritamab-R2 in routine practice. Dr. Mehta notes that tafasitamab-based therapy is generally easier to administer within community oncology settings because it does not require the step-up dosing protocols or intensive monitoring associated with bispecific antibodies. In contrast, epcoritamab-R2, although highly effective, introduces complexities such as CRS risk, ICANS monitoring, and potential need for rapid escalation to emergency or extended care services.
NP Bailey addresses patient education and adherence, emphasizing that epcoritamab-containing regimens require robust teaching around symptom recognition, infection prevention, and timely reporting of adverse effects. She underscores the importance of ensuring patients understand the seriousness of potential bispecific-related toxicities, even if uncommon, and have clear instructions for seeking care.
The segment also highlights the operational realities of community practice, where many clinicians still rely on academic centers to initiate bispecific therapy before transitioning patients back to local care. Dr. Mehta notes the value of extended care clinics that can manage lower-grade CRS on an outpatient basis, reducing hospital admissions and relieving pressure on inpatient services.
This segment equips clinicians with a pragmatic understanding of how to safely and effectively integrate novel antibody-based regimens into diverse practice environments.
Related Content:
